The desk has spent a lot of words on ketamine’s expansion, into treatment-resistant depression, suicidality, OCD, substance use, pain, and into the engineered successors meant to keep its benefit while shedding its baggage. A new systematic review of ketamine’s liver safety in mood and anxiety treatment is a reminder of the counterweight, and a careful one. Its headline is reassuring. Its fine print is where the signal sits.
What the review found
Pooling randomized trials, the review reports that at the dosing regimens typical of mood-disorder treatment, ketamine produces mostly mild, transient elevations in liver enzymes, with serious hepatotoxicity appearing rare. Across roughly 879 trial participants there were 75 hepatic adverse events, predominantly passing aminotransferase bumps, and none meeting Hy’s Law, the regulatory threshold for predicting severe drug-induced liver injury. On its face, that is a clean bill: at the doses psychiatry uses, the liver is not where ketamine’s danger lives.
The assumption holding up the headline
The reassurance rests on a dose premise, and the review is honest about it. Nearly all the documented cases of clinically significant hepatobiliary injury have occurred at substantially greater cumulative exposure than mood-disorder regimens deliver. The severe end of the literature is real and ugly, chronic exposure can produce a cholestatic injury resembling sclerosing cholangitis, with bile-duct dilation and, in the worst cases, fibrosis, and it tends to arise from sustained use rather than a single dose, clustered among heavy recreational users and high-cumulative-dose chronic-pain applications. The psychiatric safety case is essentially that mood-disorder dosing stays below the exposure where the serious damage shows up.
That assumption is exactly what the rest of the ketamine story is straining. The whole arc the desk has tracked, expansion into more indications, maintenance and repeated dosing to sustain response, and a booming off-label intravenous clinic ecosystem operating with light oversight, moves patients toward higher cumulative exposure over time. A retrospective case series has already linked repeated or continuous medically supervised ketamine to hepatobiliary events, most of them in repeated-dosing pain settings. The reassuring finding and the worrying trajectory are the same fact viewed from two ends: safe at the dose we use today, with the field steadily increasing the dose patients accumulate.
Why it matters now
This is the safety question maturing in step with the treatment. Health authorities already recommend periodic liver-function monitoring during chronic or intermittent ketamine dosing, and this review hands clinicians the evidence to take that seriously rather than treat it as boilerplate, with a concrete management path in reserve, ursodeoxycholic acid has shown promise for ketamine-induced cholestatic injury. It also feeds two threads the desk has open. It is one more cumulative-exposure harm, alongside the better-known bladder and urothelial toxicity, that defines the ceiling on how freely ketamine can be dosed as it expands. And it adds to the rationale for the cleaner successors, the hydroxynorketamine, deuterated, and R-enantiomer programs built to deliver the antidepressant effect at lower exposure and risk. A review that maps where liver injury starts is, in part, mapping the exposure ceiling those successors are trying to lift.
The caveats
They cut in both directions. The trial data is genuinely reassuring and should not be inflated into alarm: at studied psychiatric doses, serious liver injury was not seen, and a population-based pharmacovigilance analysis did not find ketamine disproportionately associated with most hepatobiliary harms relative to a known hepatotoxin. At the same time, the trial populations are selected and time-limited, real-world maintenance use runs longer and messier than a trial, and the severe cases in the literature are a warning about where the tail leads, not proof that psychiatric use reaches it. The mechanism of ketamine’s hepatobiliary toxicity is still not well understood, which makes individual susceptibility hard to predict. And the benefit is not in question; this is an argument for monitoring and for dose discipline as use scales, not for backing away from a treatment that works rapidly where little else does.
The frame
The honest reading is that ketamine’s liver risk is low at the doses psychiatry currently uses and real at the cumulative exposures its own expansion keeps nudging toward. The review’s reassurance is conditional on a dose ceiling, and the breadth thesis, the maintenance-dosing logic, and the lightly regulated clinic boom are all pressure on that ceiling. The takeaway is not fear; it is that liver monitoring belongs in the standard of care as firmly as the field’s enthusiasm for new indications, and that the exposure question deserves to be tracked as carefully as the efficacy that keeps generating the headlines.